Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes

US11267924B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11267924-B2
Application numberUS-201514971424-A
CountryUS
Kind codeB2
Filing dateDec 16, 2015
Priority dateDec 18, 2014
Publication dateMar 8, 2022
Grant dateMar 8, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.

First claim

Opening claim text (preview).

The invention claimed is: 1. A polydiallylamine block copolymer comprising a plurality of polymer chains, wherein each polymer chain is according to Formula (I): wherein: u, and v are each independently an integer from 0 to 200,000; and w is an integer from 1 to 200,000; A, B, C and D are each independently repeat units selected from Formula (II) or Formula (III); wherein Formula (II) is according to the structural formula: or a pharmaceutically acceptable salt thereof, wherein: m is 0 or 1; n is an integer from 1 to 200,000; and Formula (III) is according to the structural formula: or a pharmaceutically acceptable salt thereof, wherein: o is 0 or 1; p is an integer from 1 to 200,000; R 1 and R 2 and R 3 and R 4 are each independently selected from a group consisting of H, (C 1 -C 10 )alkyl, (C 2 -C 9 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, —O(O)C—(C 1 -C 10 )alkyl, (C 1 -C 10 )alkyl-COOH, (C 3 -C 10 )cycloalkyl-COOH, —(O)CH 3 , —OH, amide, a guanidino group represented by Formula (A) wherein a is an integer from 0 to 25, a guanidinium chloride group represented by Formula (B), wherein b is an integer from 0 to 25, a guanidinobenzene group represented by Formula (C), wherein c is an integer from 0 to 25, a dihydroxy group, represented by Formula (D), wherein d is an integer from 0 to 25, a polyethylene glycol group, represented by Formula (E) wherein e is an integer from 1 to 400, a group represented by Formula (F) wherein R z and R y are each independently selected from the group consisting of H, (C 1 -C 10 )alkyl, (C 2 -C 9 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylamine, —O(O)C-(C 1 -C 10 )alkyl, (C 1 -C 10 )alkyl-COOH, (C 3 -C 10 )cycloalkyl-COOH, —(O)CH 3 , —OH and amide, a group represented by Formula (G) wherein R x and R w are each independently selected from the group consisting of H, (C 1 -C 10 )alkyl, (C 2 -C 9 )heteroalkyl, (C 3 -C 10 )cycloalkyl, (C 2 -C 9 )heterocycloalkyl, (C 6 -C 14 )aryl, (C 2 -C 9 )heteroaryl, (C 1 -C 10 )alkylannine, —O(O)C—(C 1 -C 10 )alkyl, (C 1 -C 10 )alkyl-COOH, (C 3 -C 10 )cycloalkyl-COOH, —(O)CH 3 , cyano, cyano(C 1 -C 10 )alkyl, —OH and amide, and a point of attachment to another repeat unit of the copolymer; and wherein: (a) each polymer chain must be cross-linked with at least one other polymer chain, and (b) each polymer chain may be internally cross-linked; and wherein the molar ratio of Formula (II) monomer:Formula (III) monomer in the polydiallylamine copolymer is from 99:1 to 1:99, and the ratio of cross-linked repeat units:un-cross-linked repeat units is from 1:99 to 50:50. 2. The copolymer according to claim 1 , wherein each m is 0. 3. The copolymer according to claim 1 , wherein each m is 0 and each o is 1. 4. The copolymer according to claim 1 , wherein the ratio of Formula (II) monomer:Formula (III) monomer is from 90:10 to 5:95. 5. The copolymer according to claim 1 , wherein the copolymers has been cross-linked with a cross-linking agent. 6. The copolymer according to claim 5 , wherein the cross-linking agent is selected from epichlorohydrin, epibromohydrin, (iodomethyl)oxirane, glycidyl tosylate, glycidyl 3-nitrobenzenesulfonate, 4-tosyloxy-1,2-epoxybutane, bromo-1,2-epoxybutane, 1,2-dibromoethane, 1-bromo-2-chloroethane, 1,3-dibromopropane, bis(2-chloroethyl)amine, tris(2-chloroethyl)amine, and bis(2-chloroethyl)methylamine, 1,3-butadiene diepoxide, 1,5-hexadiene diepoxide, diglycidyl ether, 1,2,7,8-diepoxyoctane, 1,2,9,10-diepoxydecane, ethylene glycol diglycidyl ether, propylene glycol diglycidyl ether, 1,4-butanediol diglycidyl ether, glycerol diglycidyl ether, 1,3-diglycidyl glyceryl ether, N,N-diglycidylaniline, neopentyl glycol diglycidyl ether, diethylene glycol diglycidyl ether, 1,4-bis(glycidyloxy)benzene, resorcinol digylcidyl ether, 1,6-hexanediol diglycidyl ether, trimethylolpropane diglycidyl ether, 1,4-cyclohexanedimethanol diglycidyl ether, 1,3-bis-(2,3-epoxypropyloxy)-2-(2,3-dihydroxypropyloxy)propane, 1,2-cyclohexanedicarboxylic acid diglycidyl ester, 2,2′-bis(glycidyloxy)diphenylmethane, bisphenol F diglycidyl ether, 1,4-bis(2′,3′-epoxypropyl)perfluoro-n-butane, 2,6-di(oxiran-2-ylmethyl)-1, 2,3,5,6,7-hexahydropyrrolo[3,4-f]isoindol-1,3,5,7-tetraone, bisphenol A diglycidyl ether, ethyl 5-hydroxy-6,8-di(oxiran-2-ylmethyl)-4-oxo-4h-chromene-2-carbo xylate, bis[4-(2,3-epoxy-propylthio) phenyl]-sulfide, 1,3-bis(3-glycidoxypropyl)tetramethyldisiloxane, 9,9-bis[4-(glycidyloxy) phenyl]fluorene, triepoxyisocyanurate, glycerol triglycidyl ether, N,N-diglycidyl-4-glycidyloxyaniline, isocyanuric acid (S,S,S)-triglycidyl ester, isocyanuric acid (R,R,R)-triglycidyl ester, triglycidyl isocyanurate, trimethylolpropane triglycidyl ether, glycerol propoxylate triglycidyl ether, triphenylolmethane triglycidyl ether, 3,7,14-tris[[3-(epoxypropoxy)propyl]dimethylsilyloxy]-1, 3,5,7,9,11,14-heptacyclopentyltricyclo[7.3.3.15,11]heptasiloxane, 4,4′-methylenebis(N, N-diglycidylaniline), bis(halomethyl)benzene, bis(halomethyl)biphenyl and bis(halomethyl)naphthalene. 7. The copolymer according to claim 6 , wherein the cross-linking agent is epichlorohydrin.

Assignees

Inventors

Classifications

  • A61K31/785Primary

    Polymers containing nitrogen · CPC title

  • Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

  • by a single or double bond to nitrogen · CPC title

  • Three-membered rings · CPC title

  • Diallylamine · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11267924B2 cover?
Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine. Polydiallylamine copolymers are often crosslinked. The polydiallyamine copolymers are useful as pharmaceutical compositions and may be used in the treatment of type 2 diabetes and for mitigating the complications of type 2 diabetes.
Who is the assignee on this patent?
Genzyme Corp
What technology area does this patent fall under?
Primary CPC classification A61K31/785. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).